Status:
COMPLETED
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study was to evaluate the anti-tumor activity of single agent BYL719, INC280, LDK378 and MEK162 in advanced NSCLC patients carrying specific molecular alterations. There is a grea...
Detailed Description
To enter the screening phase of the study, the subjects' molecular alterations were determined using locally validated methodologies from a newly obtained tumor sample (preferred) or the most recent a...
Eligibility Criteria
Inclusion
- Advanced (stage IIIB or stage IV) NSCLC
- Must have specific molecular alterations
Exclusion
- Symptomatic central nervous system (CNS) metastases which are neurologically unstable or requiring increasing doses of steroids within the 4 weeks prior to study entry to control their CNS disease
- Radiation therapy within ≤ 4 weeks prior to study entry, with the exception of limited field palliative radiotherapy for bone pain relief.
- Any other malignancies within the last 5 years before study entry
- Major surgery ≤ 2 weeks prior to study entry or who have not recovered from side effects of such therapy
Key Trial Info
Start Date :
January 20 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2019
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT02276027
Start Date
January 20 2015
End Date
October 15 2019
Last Update
December 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Guangzhou, Guangdong, China, 51000